Suscribirse

Pre-medication with Gabapentin is associated with significant reductions in nausea and vomiting after shoulder arthroscopy: A meta-analysis - 05/12/19

Doi : 10.1016/j.otsr.2019.09.023 
Anwar ul Huda a, , Rob W. Jordan b, Matthew Daggett c, d, Adnan Saithna c, d, e
a Security Forces Hospital, Kingdom of Saudi Arabia, Anesthesia, Riyadh, Saudi Arabia 
b Robert Jones and Agnes Hunt Orthopaedic Hospital, UK 
c Sano Orthopedics, Kansas City, USA 
d Kansas City University of Medicine and Biosciences, Missouri, USA 
e School of Science and Technology, Nottingham Trent University, Nottingham, UK 

Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Introduction

Arthroscopic shoulder surgery is increasingly performed as a day case procedure. Nausea, vomiting and inadequate pain control are the most frequent reasons for reattendance or failed discharge. Gabapentin is advocated as an adjunct to mitigate these symptoms and its use in shoulder arthroscopy may provide improved post-operative symptom control. The aim of this study was to perform a meta-analysis of studies evaluating the role of gabapentin in the peri-operative management of shoulder arthroscopy.

Hypothesis

Gabapentin is associated with significant improvements in post-operative nausea, vomiting and pain control after shoulder arthroscopy.

Material and methods

A systematic review using Medline was conducted in accordance with the PRISMA guidelines. Randomised controlled trials studies reporting on patients >15 years old receiving either preoperative gabapentin or placebo before any shoulder arthroscopic surgery were considered for eligibility. Studies were appraised against the Consolidated Standards of Reporting Trials (CONSORT) checklist. A meta-analysis was performed using Review Manager 5.3.

Results

Four randomized controlled trials were identified for inclusion (n=227). Meta-analysis demonstrated a beneficial effect of gabapentin in preventing nausea and vomiting in the postoperative period (Odds Ratio 0.30, p=0.04). However, pooled data analysis did not show significant advantage in using gabapentin for postoperative pain control (p=0.11), although one study demonstrated a significant reduction in opioid consumption after gabapentin. No significant difference was reported in post-operative dizziness or sedation between the groups.

Discussion

Gabapentin did not show any significant benefit in postoperative pain control but is associated with significant reductions in post-operative nausea and vomiting after shoulder arthroscopy.

Level of evidence

I, meta-analysis.

El texto completo de este artículo está disponible en PDF.

Keywords : Shoulder arthroscopy, Gabapentin, Pain, Nausea, Vomiting


Esquema


© 2019  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 105 - N° 8

P. 1487-1493 - décembre 2019 Regresar al número
Artículo precedente Artículo precedente
  • Previous arthroscopic Bankart repair is an independent risk factor for an inferior outcome after Latarjet procedure
  • Tapio Flinkkilä, Rony Knape, Mika Nevalainen, Kai Sirniö, Pasi Ohtonen, Juhana Leppilahti
| Artículo siguiente Artículo siguiente
  • Clinical and radiological outcomes of 17 reverse shoulder arthroplasty cases performed after failed humeral head resurfacing
  • Pierre Gaeremynck, Thomas Amouyel, Marc Saab, Benjamin Gadisseux, Kevin Soudy, Christophe Szymanski, Carlos Maynou

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.